Document Detail


FDG-PET Response-adapted Therapy: Is 18F-Fluorodeoxyglucose Positron Emission Tomography a Safe Predictor for a Change of Therapy?
MedLine Citation:
PMID:  24287070     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is the most accurate tool for staging, treatment monitoring, and response evaluation in Hodgkin lymphoma (HL). Early determination of treatment sensitivity by FDG-PET is the best tool to guide individualized, response-adapted treatment. Several ongoing or recently completed trials have investigated the use of FDG-PET/CT for early response-adapted HL therapy. The results are encouraging, but the data are immature, and PET response-adapted HL therapy is discouraged outside the setting of clinical trials. PET/CT looks promising for selection of therapy in relapsed and refractory disease, but the role in this setting is still unclear.
Authors:
Martin Hutchings
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Hematology/oncology clinics of North America     Volume:  28     ISSN:  1558-1977     ISO Abbreviation:  Hematol. Oncol. Clin. North Am.     Publication Date:  2014 Feb 
Date Detail:
Created Date:  2013-11-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8709473     Medline TA:  Hematol Oncol Clin North Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  87-103     Citation Subset:  IM    
Copyright Information:
Copyright © 2014 Elsevier Inc. All rights reserved.
Affiliation:
Department of Haematology, Rigshospitalet, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. Electronic address: martin.hutchings@gmail.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Induction Therapy for Advanced-stage Hodgkin Lymphoma: Late Intensification (ABVD Chemotherapy Follo...
Next Document:  Customized targeted therapy in hodgkin lymphoma: hype or hope?